Subjects able and willing to give written informed consent (or legally acceptable representative or impartial witness when applicable) and is available for entire study
Patients meet the criteria of either group below:
Patients that are diagnosed with RA according to the revised 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Rheumatoid Arthritis Classification Criteria (table 1)
Patients are experiencing an exacerbation defined as an increase in DAS28 \> 1.2 or \> 0.6 if DAS28 ≥ 3.2 compared to last DAS28 measurement (maximum six months before)
The exacerbation is refractory to systemic cDMARDs for at least three months, defined as 'no response' according to the EULAR response criteria (table 2)
Wrist arthritis, that is diagnosed clinically, is the predominant symptom
Patients that are diagnosed with PsA according to the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria (table 3)
Patients are experiencing an exacerbation defined as an increase in DAS28 \> 1.2 or \> 0.6 if DAS28 ≥ 3.2 compared to last DAS28 measurement (maximum six months before)
The exacerbation is refractory to systemic cDMARDs for at least three months, defined as 'no response' according to the EULAR response criteria (table 2)
Wrist arthritis, that is diagnosed clinically, is the predominant symptom
You may not be if
Previous or current treatment with biological (b) DMARDs
Current inflammatory joint disease other than RA or PsA (e.g. gout, reactive arthritis, Lyme disease)
Subjects who are pregnant or intend to become pregnant during the study
Intra-articular corticosteroids injection in the wrist in the last 6 months
Previous wrist surgery
Severe osteoarthritis with malformations of the wrist
Congenital abnormalities of wrist function or motion
